Atlas Trials

Recurrent Ovarian Endometrioid Adenocarcinoma

10 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Ovarian Endometrioid Adenocarcinoma

RecordFirmDate
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589)National Cancer Institute (NCI)2022-06-30
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800)National Cancer Institute (NCI)2021-06-10
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (NCT04092270)National Cancer Institute (NCI)2020-05-07
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04034927)National Cancer Institute (NCI)2019-12-04
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer (NCT03348631)National Cancer Institute (NCI)2019-05-01
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02839707)National Cancer Institute (NCI)2017-06-23
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02446600)National Cancer Institute (NCI)2016-03-28

Track Recurrent Ovarian Endometrioid Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.